Format

Send to

Choose Destination
Curr Opin Mol Ther. 2004 Aug;6(4):451-7.

Technology evaluation: ABT-510, Abbott.

Author information

1
Radboud University Medical Center, Department of Pathology, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. J.Westphal@obgyn.umcn.nl

Abstract

ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.

PMID:
15468604
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center